Contact Information: Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper (212) 838-1444 Public Relations Contact: Rubenstein Associates, Inc. Robin Wagge (212) 843-8006
Delcath Systems' President and CEO Richard Taney to Present at Two Medical Technology Conferences
| Source: Delcath Systems, Inc.
NEW YORK, NY--(Marketwire - October 21, 2008) - Delcath Systems, Inc. (NASDAQ : DCTH ) a leading
developer of regional therapy for liver cancer announced today that
President and CEO Richard Taney will participate in a Panel Discussion on
"Combination Products: A Convergence of Technologies and Market
Opportunities" at the Medical Device & Manufacturing Conference, Oct 22,
2008, 12:30pm-1:15pm at the Minneapolis Convention Center. Mr. Taney will
also be making a presentation on the Delcath PHP technology at the
Investment in Innovation (In3) East Conference to be held on October 23rd,
9:30am-10:00am at the Westin Copley Place in Boston.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company is testing a proprietary, patented drug
delivery system for the treatment of liver cancers. Delcath's novel drug
delivery platform is testing the delivery of ultra-high doses of
anti-cancer drugs to the liver while preventing these high doses of drug
from entering the patient's bloodstream. The Company is currently
enrolling patients in Phase III and Phase II clinical studies for the
treatment of liver cancers using high doses of melphalan. The Company's
intellectual property portfolio consists of twenty-eight patents on a
worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug-delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
date they are made.